Chemotherapy-Induced Anemia Pipeline: 3+ Companies Advancing Novel Erythropoietic and Supportive Therapies | DelveInsight

Chemotherapy-Induced Anemia (CIA) is a common and debilitating side effect of cancer treatment, significantly impacting patients' quality of life, fatigue levels, and treatment adherence. With limited therapeutic options-mainly erythropoiesis-stimulating agents (ESAs) and transfusions-there is a pressing need for safer and more effective alternatives. 3+ pharmaceutical innovators, including Roche, Akebia Therapeutics, Vifor Pharma, and Astellas, are advancing next-generation agents in the CIA pipeline. These include hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors, novel ESAs, and hepcidin-targeted therapies aimed at enhancing erythropoiesis and iron utilization. This evolving pipeline holds promise for transforming supportive oncology care by reducing transfusion dependency and improving hematologic recovery in cancer patients undergoing chemotherapy.

DelveInsight's "Chemotherapy Induced Anemia Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the chemotherapy-induced anemia market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging chemotherapy-induced anemia drugs, the chemotherapy-induced anemia pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for chemotherapy-induced anemia and uncover key opportunities @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Chemotherapy-Induced Anemia Pipeline Report
• DelveInsight's chemotherapy-induced anemia pipeline analysis depicts a strong space with 3+ active players working to develop 3+ pipeline drugs for chemotherapy-induced anemia treatment.
• The leading chemotherapy-induced anemia companies include FibroGen, Zydus Cadila, SBI Pharmaceuticals, and others, which are evaluating their lead assets to improve the chemotherapy-induced anemia treatment landscape.
• Key chemotherapy-induced anemia pipeline therapies in various stages of development include Roxadustat, Desidustat, Aminolevulinic acid, and others.
• In June 2024, the FDA approved RYTELO, an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS) who have transfusion-dependent anemia. This approval specifically targets patients who require four or more red blood cell units over 8 weeks and have either not responded to, lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs).

Request a sample and discover the recent breakthroughs happening in the chemotherapy-induced anemia pipeline landscape @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Anemia Overview
Chemotherapy-induced anemia (CIA) arises from multiple factors, including tumor-related blood loss, bone marrow suppression, inflammation-driven functional iron deficiency, and impaired erythropoiesis. It is a common and serious side effect of cancer treatment that can reduce quality of life, cause fatigue, and potentially disrupt or delay chemotherapy schedules. CIA is influenced by numerous patient- and treatment-specific variables such as the type of cancer, chemotherapy regimen, baseline hemoglobin levels, renal function, nutritional status, and timing of interventions. Managing CIA is complex due to the variability in patient symptoms and disease profiles, especially in hematologic cancers where it is more prevalent than in solid tumors. The primary goals of treatment are symptom relief and improved quality of life. Standard interventions include red blood cell transfusions, erythropoiesis-stimulating agents (ESAs), and iron therapy. Effectively addressing CIA is associated with better chemotherapy outcomes.

Find out more about chemotherapy-induced anemia medication @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Anemia Treatment Analysis: Drug Profile
Roxadustat: FibroGen
Roxadustat is a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that stimulates erythropoiesis by boosting endogenous erythropoietin, enhancing iron availability, and reducing hepcidin. This drug has been shown to increase red blood cell production while keeping plasma erythropoietin levels within the normal physiological range, even in the presence of inflammation, without the need for intravenous iron. Roxadustat is approved in China, Japan, Europe, Chile, and South Korea for treating anemia in chronic kidney disease (CKD) patients, both on and off dialysis. However, the U.S. FDA issued a complete response letter for its NDA submission for CKD-related anemia in August 2021. It is currently in Phase 3 clinical trials in the U.S., Europe, and China for myelodysplastic syndromes (MDS)-associated anemia, and in a Phase 2 U.S. trial for chemotherapy-induced anemia (CIA).

SPP-003: SBI Pharmaceuticals
SBI Pharmaceuticals has submitted an Investigational New Drug Application (IND) to the U.S. FDA for a Phase 1 clinical trial of a 5-aminolevulinic acid (5-ALA)-based formulation to treat anemia caused by cancer chemotherapy. 5-ALA, a naturally occurring amino acid produced in mitochondria, is crucial for energy production in the form of hemes and cytochromes. Its production tends to decrease with age. This compound, found in food sources such as radish sprouts, red wine, and shochu distillation remnants, is expected to improve anemia symptoms by activating hematopoietic functions.

Learn more about the novel and emerging chemotherapy-induced anemia pipeline therapies @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Chemotherapy-Induced Anemia Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Chemotherapy-Induced Anemia Pipeline Report
• Coverage: Global
• Key Chemotherapy-Induced Anemia Companies: FibroGen, Zydus Cadila, SBI Pharmaceuticals, and others.
• Key Chemotherapy-Induced Anemia Pipeline Therapies: Roxadustat, Desidustat, Aminolevulinic acid, and others.

Dive deep into rich insights for drugs used for chemotherapy-induced anemia treatment; visit @ https://www.delveinsight.com/report-store/chemotherapy-induced-anemia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Chemotherapy-Induced Anemia Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Chemotherapy-Induced Anemia Pipeline Therapeutics
6. Chemotherapy-Induced Anemia Pipeline: Late-Stage Products (Phase III)
7. Chemotherapy-Induced Anemia Pipeline: Mid-Stage Products (Phase II)
8. Chemotherapy-Induced Anemia Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.